Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Lilly is scheduled to report third-quarter earnings before the market opens on Wednesday, before it hosts a call for ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.